PROFESSIONAL PREPARATION    Chung Shan Medical University Taichung, Taiwan School of Medicine M.D., 1985 Harvard University  Boston, USA School of Public Health M.P.H. 1999 Chung Shan Medical University Taichung, Taiwan Institute of Medicine Ph.D. 2015 APPOINTMENTS Professor School of Medicine, Chung Shan Medical University 2015- Present Vice president Chung Shan Medical University 2020-Present Superintendent Chung Shan Medical University Hospital 2020-Presnet Professor Terence Ming-Che Tsai, who served as trauma surgeon and Director of Emergency Department  in  National Cheng Kung University Hospital since 1999. He was appointed by the Ministry of Health as the Taiwanese disaster relief team leader for the Tsunami in Indonesia 2004. He retired in 2010, became director of the College of Medicine in Chung Shan Medical University in 2017. Currently, he is the Superintendent of Chung Shan Medical University Hospital starting in 2020. Dr. Tsai was interested in medical education and hospital management, who successfully led CSMUH during the Covid-19 pandemic. He received his MD degree at CSMU in 1985, Master of Public Health in Harvard U. in 1999, and PhD in 2015. He is a diligent scholar in both academic and clinical fields, full of experiences in problem solving and communication skills.

Education

2014, Harvard University, Epidemiology, ScD

2004, National Taiwan University, Clinical Research Institute, MSc

1997, National Taiwan University, Medicine, MD

 

Current Position

1. Director, Department of Information Management , Ministry of Health and Welfare

2. Professor, Department of Emergency Medicine, College of Medicine, National Taiwan University

3. Consultant, NTUH Center for Intelligent Healthcare

2009.08~2010.07 Director of Neurosurgery, Taipei Municipal Wanfang Hospital 

2011.03~2012.06 Director of Information Center, Department of Health, Executive Yuan

2012.07~2019.03 Director of Office of International Cooperation, Ministry of Health and Welfare 

2019.03~ Professor and Director, Graduate Institute of Date Science, Taipei Medical University

2019.12~ Chief Data Officer, Office of Data Science, Taipei Medical University

Mui is a Director of Product Development at IQVIA, managing the OMOP Factory. Mui’s area of expertise include software development, data conversions, agile process, and project management. The OMOP Factory has been performing OMOP ETL conversions on over 12 different datasets in 6 different countries. Mui has gained extensive knowledge working on large patient databases in the OMOP model and the standard vocabularies that are needed to support these conversions.

Mui is an active contributor to the community through various OHDSI working groups. She is one of the co-leaders of the China OMOP CDM/Vocabulary working group. She leads two of the sub-working groups within the THEMIS working group. She has and continues to perform OMOP tutorial trainings to many different organizations and conference, such as the OHDSI Symposiums, the China Hackathons, and individual universities.

Yu Shyr received his PhD in biostatistics from the University of Michigan in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine, where he won the Hawiger Award for Excellence in Teaching in 2012 and was inducted into the Academy for Excellence in Education in 2013. Renowned for his development of integrative methods and high-impact applications of those methods, Shyr is an elected fellow of the American Statistical Association (ASA), the American Association for the Advancement of Science (AAAS), and the American Association for Cancer Research (AACR), and he holds an honorary doctorate from National Cheng Kung University. He has published more than 550 peer-reviewed papers (h-index = 124) and serves as an associate editor for JAMA Oncology and Journal of Thoracic Oncology. Shyr has presented more than 450 invited talks, workshops, and courses around the world and currently co-directs the BMSF-AACR Design and Implementation of Clinical Trials Workshop, part of Bristol Myers Squibb Foundation’s initiative to diversify clinical research.

In demand as an expert on external advisory boards and data safety monitoring committees across the United States, Shyr was a voting member of the US Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee and has served on dozens of National Cancer Institute (NCI) study sections and panels. As principal investigator of the Barrett’s Esophagus Translational Research Network Coordinating Center (BETRNetCC), funded by an NCI U24 grant, Shyr led a team that provided crucial support for the collection, management, analysis, and dissemination of data among multiple research centers. His current projects include developing novel statistical and bioinformatic tools for biomedical research and improving experiment and clinical trial design, particularly in the areas of proteomics and genomics, with special focus on single cell RNA sequencing.

Dr Yaolong Chen is a professor and a guideline methodologist at the Evidence Based Medicine Centre of Lanzhou University. He is co-Director of WHO Collaborating Centre for Guideline Implementation and Knowledge Translation. He studied guideline development in McMaster University between September 2010 and March 2011 as a visiting research fellow and worked for the WHO Guidelines Review Committee between September 2013 and March 2014 as a volunteer.

 

Professor Chen is the Co-Founder of ADVANCED (AI-Driven deVelopment and AssessmeNt of healthCare guidElines and standard), which aims to empower healthcare with AI to deliver personalized, high-quality recommendations for all. He has authored and co-authored more than 500 peer reviewed articles on evidence-based medicine and practice guidelines. He has been invited to give numerous presentations in Cochrane colloquiums, GIN conferences and other national and international symposiums. He was involved in the development of more than 100 national and international practice guidelines over the last ten years.

Medical Doctor, Professor, Doctoral Supervisor, and Postdoctoral Cooperative
Supervisor. He is a specially-appointed professor of leading talents in Anhui
Province, a reserve candidate for academic and technical leaders in Anhui
Province, a recipient of the Anhui Youth May 4th Medal, an advanced worker in
Anhui Province, and an outstanding youth in Anhui Province. He once served as
the deputy director of the Hefei Municipal Health Commission. Currently, he is
the vice dean of the School of Public Health of Anhui Medical University, the
director of the Medical Data Processing Center, the deputy director of the
Institute of Kidney Diseases and Inflammatory Immune Diseases, and the deputy
director of the management office of the Inflammatory Immune Diseases Laboratory
of Anhui Province. He serves as the editor-in-chief of "Clinical and Molecular
Epidemiology", the deputy editor-in-chief of "International Journal of Rheumatic
Diseases", the deputy editor-in-chief of "Frontiers in Public Health", a member
of the editorial board of "Current Pharmaceutical Design", and the executive
editorial board member of "Chinese Journal of Disease Control and Prevention".
At present, as the first author or corresponding author, he has published more
than 150 papers in SCI journals such as "JAMA Pediatrics", "Nature Reviews
Rheumatology", and "Annals of the Rheumatic Diseases", with an H-index of 44. He
has won one first prize of the Chinese Medical Science and Technology Award, one
second prize of the Anhui Science and Technology Progress Award, and one third
prize of the Anhui Science and Technology Progress Award. He has presided over
four National Natural Science Foundation of China projects. He is listed in the
global top 2% leading scientists list. In 2023, he ranked third in the academic
influence of scholars in the field of rheumatology and immunology in China. He
is listed in the Expertscape global expert ranking list for systemic lupus
erythematosus and ranks first in China. One of his papers was selected as the
first in the TOP100 high-value papers in the field of rheumatology and
immunology in China in 2022. He is a member of the teaching team of the first
batch of national excellent resource sharing courses "Epidemiology" and one of
the main lecturers of the first batch of national first-class undergraduate
courses "Epidemiology". He has edited/co-edited three national planning
textbooks. He has won three first prizes and two third prizes of Anhui Teaching
Achievement Awards.

Gema Hernández is a recognized expert in RWE research. In her role, she supports and educates investigators on leveraging TriNetX and its datasets for academic research, drawing on her extensive knowledge of the potential and challenges of healthcare RWD.
She holds a BSc in Biomedical Engineering, as well as an MSc and a PhD (Cum Laude) in Artificial Intelligence from the Polytechnic University of Madrid. Her research has been published in numerous high-impact scientific journals, including Blood Cancer Journal, Haematologica, and Diabetologia.

Prof. Chun-Ying Wu received his M.D. degree from National Taiwan University (NTU) in 1991, M.P.H. degree from Harvard School of Public Health in 1993, LL.B. degree from College of Law in 2000, Tunghai University, LL.M. degree from Harvard Law School in 2023, and Ph.D. degree from NTU in 2007. Prof. Wu is currently the Chair Professor and Director of Biomedical Informatics, at National Yang Ming Chiao Tung University (NYCU) and the Director of both Health innovation Center and Microbiota Research Center at NYCU. He establishes and serves as the Director of Taiwan National Human Microbiota Core Facility, which is supported by Taiwan National Science and Technology Council (NSTC) since 2023. He also establishes Taiwan Microbiota Consortium (TMC) and serves as the first TMC President since 2017. He is now the Editor-in-Chief of Advances in Digestive Medicine, associate editor of the Journal of Gastroenterology and Hepatology, and editorial member of Gut.
Prof. Wu’s research interests focus on digestive cancer translational research, health big data and AI research, microbiota research, and legal research. Prof. Wu has published more than 300 articles in SCI journals, including JAMA, JAMA Int Med, JAMA Ped, J Clinical Oncology, Gastroenterology, Gut, J of Hepatology, Int J Surg, Hepatology, etc. He is listed as one the World’s Top 2% Scientists with H-index=64 and more than 15,000 citations. He gets several patents, such as gastric cancer screening, hepatitis B virus quantitative detection methods, microbiota to treat metabolic syndrome, etc. Prof. Wu is the winner of the 2021 and 2015 Outstanding Research Awards of Taiwan NSTC, the 2016 National Innovation Award, and the 2015 Asia-Pacific Emerging Leadership Award. Prof. Wu published 4 law textbooks and more than 100 law articles, which contribute to change the Taiwan malpractice litigation system. It is the reason.

that Prof. Wu got the 2018 Taiwan Medical Model Award from Taiwan Medical Association.

Professor Ian Wong is a professor and former Head of Department of Pharmacology and Pharmacy, University of Hong Kong. He is also the holder of Regius Chair in Pharmacy at the Aston University, UK.
As an academic pharmacist with research expertise in big data analytics and neuropsychopharmacology. He has led many research programmes in the UK, European and Hong Kong. Professor Wong has over 600 publications with publication in prominent journals including Nature portfolio journals, JAMA Network Journals, The Lancet family journals, BMJ journals. According to Clarivate Analytics' Essential Science Indicators, Professor Wong has been a top 1% scholar in pharmacology and pharmacy research from 2015 to 2024.
In recognition of his research, Professor Wong has received numerous awards for his work as an academic pharmacist. He was awarded the Chemist and Druggist Pharmacy Practice Research Conference Medal from the Royal Pharmaceutical Society of Great Britain in 2004, an Honorary Fellowship from the Royal College of Paediatrics and Child Health in the UK in 2011, an Honorary Fellowship from the College of Pharmacy Practice in Hong Kong in 2013, and a Fellowship from the Royal Pharmaceutical Society in 2013, a Fellowship from British Pharmacological Society and International Society of Pharmacovigilance in 2020.

Edward is a Professor at the School of Pharmacy, National Cheng Kung University, Taiwan. He has expertise in the use of a variety of healthcare databases across Asia, Oceania, North America, and Europe in the conduct of international multi-database pharmacoepidemiologic research. His research interests include the safety and effectiveness of psychotropic, rheumatologic, and oncologic medications. He has published 100+ research articles in top journals such as BMJ, JAMA Internal Medicine, Annals of Internal Medicine, and Lancet Psychiatry. He has served as an Associate Editor of Pharmacoepidemiology and Drug Safety since 2013. He served as the chair of the Asian Pharmacoepidemiology Network (AsPEN) (2016-2018). He is an active Neurological and mental health Global Epidemiology Network (NeuroGEN) member. He was awarded the Fellow of the International Society for Pharmacoepidemiology (FISPE) designation in 2023.

Professor Matthew Brown, an internationally renowned clinician-scientist, joined Genomics England as Chief Scientific Officer in 2021.
Prior to this he served as Director of the National Institute for Health Research (NIHR) Guy’s and St Thomas’ Biomedical Research Centre. He is also Professor of Medicine within the Faculty of Life Sciences and Medicine, King’s College London.
Professor Brown trained as a clinician-scientist and a rheumatologist in Australia and the UK. Previous positions include Professor of Musculoskeletal Sciences at the University of Oxford; Director of the Australian Translational Genomics Centre, Distinguished Professor, and Director of Genomics at the Queensland University of Technology; and Director of The University of Queensland Diamantina Institute and Professor of Immunogenetics at The University of Queensland.
He has made contributions to the development of gene-mapping approaches in human diseases and genome-wide association study methodology, leading to the discovery of thousands of genetic variants, with a particular interest in ankylosing spondylitis, rheumatoid arthritis, and osteoporosis.
In the genetics of rare human diseases, he has identified genes responsible for monogenic forms of arthritis, ectopic bone development, and skeletal dysplasias. He has also led efforts in Australia to translate research sequencing capability into precision medicine programs for cancer patients.
Professor Brown was elected a Fellow of the Australian Academy of Sciences in recognition for his achievements in genetics research. He still practises medicine, in the specialty of rheumatology, with a particular focus on axial spondyloarthropathies.

Dr James Cheng-Chung Wei obtained his MD degree in National Yang Ming University and PhD degree in Chung Shan medical university. After training in rheumatology and clinical immunology at Taichung Veterans General Hospital and Kaohsiung Veterans General Hospital, he undertook a fellowship at the Royal National Hospital for Rheumatic Diseases in Bath, UK, under the supervision of Professor Andrei Calin, and a research fellowship at the University of California, Los Angeles (UCLA) under Professor David Yu, investigating the clinical and pathogenesis of spondyloarthritis. 

He had conducted over 200 global clinical trials and about 50 investigator-initiated clinical trials. He is currently a full member of the ACR, GRAPPA and ASAS. He is also the scientific advisory board of the APALR, and Editor-in-Chief of the International Journal of Rheumatic Diseases and associate editor of the Frontiers in Immunology.

Dr Wei had published more than 600 papers in peer-reviewed SCI journals , such as the NEJM, JAMA, JAMA Network Open, Lancet, Annals of the Rheumatic Diseases, Arthritis & Rheumatology, JAAD, Rheumatology, Journal of Autoimmunity  & International Journal of Rheumatic Diseases…etc.

His major research interests are translational research in ankylosing spondylitis, clinical trials and big data research in rheumatology.

1. Director, Health Data Science Center, Chung Shan Medical University Hospital
2. Assistant Professor, Institute of Medicine, Chung Shan Medical University
3. Supervisor, Taiwan Medical Big Data Research Society

1. Research fellow, Center for Health Data Science, Chung Shan Medical University Hospital
2. Academic Teaching Rank Accreditation Certificate Assistant Professor
3. Business Intelligence Data Analyst (IBM SPSS Software Certificate)

1. Vice Supervisor of Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital
2. Directors of Taiwan Medical Big Data Research Society
3. Committee Member of the Youth Committee, Taiwan Evidence-Based Medicine Association

1. Consultant of Pediatrics, Asthma, Allergy, Immunology and Rheumatology.
2. China Medical University Children’s Hospital (CMUCH), Taichung, Taiwan.
3. Executive Editor of Journal of Microbiology, Immunology and Infection
4. Associate Editor of International Journal of Rheumatic Diseases

1. Resident Physician, Department of Internal Medicine, Kaohsiung Veterans General Hospital
2. Attending Physician, Department of Internal Medicine, Division of Chest Medicine and Critical Care Medicine, Kaohsiung Veterans General Hospital
3. Executive Director, Taiwan Medical Big Data Research Society

1. Deputy Director, Data Finance Innovation Center, National Yang Ming Chiao Tung University
2. Member, National Council for Sustainable Development, Executive Yuan, Taiwan Govt.
3. Member, National Action Plan, Executive Yuan, Taiwan Govt.

1. Professor and Chair, Department of Health Policy ang ManagementChun Shan Medical University
2. Vice President, Taiwan Medical Tourism Development Assosiation
3. Executive Supervisor, Taiwan Medical Big Data Research Society

1. Professor and Chair of Department of Public Health, Chung Shan Medical University, Taichung, Taiwan.